Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity.
about
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicityAntiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamicsAntiprogestins in gynecological diseases.Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.Drug Repurposing for Cancer Therapy.Synergistic lethality of mifepristone and LY294002 in ovarian cancer cellsThe unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis.Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.
P2860
Q33554192-337A0158-3023-4A17-A539-989B320D1F31Q33914314-C12FFB03-0B65-4602-BC13-895BCC05602FQ34285363-64802173-4FF4-4B81-896B-DE1932312B15Q34564141-0BACC81B-337E-4D7E-9596-7384C7715593Q34587636-F1C7EDD0-D983-47D5-9BF7-9FEA86F5B8E8Q35650181-D53E8AA6-04E9-4E91-B179-B5FD023F72FFQ35947321-1F28AF5C-69DF-4AED-A2BE-52C31CC396E1Q36229392-2EA06D8D-A65C-4258-8B23-899DF411BF62Q36607965-2A285F92-3370-44D9-B521-2A6DC0683EA2Q38192568-EE538D95-B1AC-460D-A113-44429542D2ACQ41914993-5A40B198-40FA-4814-B36F-A5463A8575B3Q53689778-ADBC128E-A7C2-4665-9DF5-34804A9D4F51
P2860
Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Resistance to cisplatin does n ...... to mifepristone cytotoxicity.
@en
Resistance to cisplatin does n ...... to mifepristone cytotoxicity.
@nl
type
label
Resistance to cisplatin does n ...... to mifepristone cytotoxicity.
@en
Resistance to cisplatin does n ...... to mifepristone cytotoxicity.
@nl
prefLabel
Resistance to cisplatin does n ...... to mifepristone cytotoxicity.
@en
Resistance to cisplatin does n ...... to mifepristone cytotoxicity.
@nl
P2093
P2860
P356
P1476
Resistance to cisplatin does n ...... to mifepristone cytotoxicity.
@en
P2093
Alicia A Goyeneche
Carlos M Telleria
Elizabeth M Freeburg
Erin E Seidel
P2860
P2888
P356
10.1186/1475-2867-9-4
P577
2009-02-17T00:00:00Z
P5875
P6179
1052541798